BSEBoard Meeting9h ago · 23 Jul 2026, 03:42 pm

Please find enclosed outcome of the Board Meeting held on July 23, 2026, inter alia, approving the unaudited financial results for the quarter ended June 30, 2026, as detailed in the enclosed letter.

Thyrocare Technologies Ltd · 539871

✦ AI SummaryResults

Thyrocare Technologies Ltd announced the outcome of its Board Meeting held on July 23, 2026, where it approved unaudited financial results for the quarter ended June 30, 2026, and re-appointed Ernst & Young LLP as Internal Auditor for the Financial Year 2026-27.

Analysis Scores

Earnings Impact6/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk3/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Thyrocare Technologies Ltd - 539871 - Board Meeting Outcome for Outcome Of The Board Meeting Held On July 23, 2026

Attachments (1)

📄

19803c12-c390-4c6c-9157-f6a0330d0cd5.pdf

pdf

Download →
View document text
July 23, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza Phiroze Jeejeebhoy Towers B(SaYnMdrBaO KLu:r TlaH CYoRmOpCleAxR, E ) D(SaClaRlI SPt rCeOeDt, E: 539871) Bandra (E), Mumbai - 400051 Mumbai- 400001 Subject: Outcome of the Board Meeting held on Thursday, July 23, 2026 1) Unaudited Standalone and Consolidated Financial Results along with the Limited Review Report for the quarter ended June 30, 2026; and 2D)ear RSeir-A/Mppaodianmtm, ent of Internal Auditor for the Financial Year 2026-27 Pursuant to the provisions of Regulation 30 and other applicable provisions of the Securities (“SEBI Listing Regulations and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, Board ., Thursday, July 23, 2026, 2015 ”), we wish to inform you that the Board of Directors of the Company (“ ”), at its meeting held today, i.e inter alia, considered and approved the following matters: 1. Unaudited Standalone and Consolidated Financial Results along with the Limited Review Report for the quarter ended June 30, 2026 The Board has approved the Unaudited Standalone and Consolidated Financial Results of the Company along with the Limited Review Report for the quarter ended June 30, 2026. Pursuant to Regulation 33(3) of the SEBI Listing Regulations, copies of the Standalone and Consolidated unaudited financial reAsnunltesx fuorr eth Ae quarter ended June 30, 2026, along with the Limited Review Reports on the said financial results issued by the Statutory Auditors 2. Rofe t-hAep Cpoominptamneyn atr eo fa Itntatcehrenda la sA aund itor for the Ftion athnicsi laelt tYeera.r 2026-27 M/s. Ernst & Young LLP, Chartered Accountants Based on the recommendation of the Audit Committee, the Board has approved the re- appointment of , as Internal Auditors of the Company for the Financial Year 2026-27. Disclosure of information pursuaAnnt ntoe xRuergeu lBat ion 30 of SEBI Listing Regulations, read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is annexed as to this letter. The above disclosures are also being made available on the website of the Company at https://investor.thyrocare.com. The Board Meeting commenced at 2:45 P.M. and concluded at 03:35 P.M. This is for your information and records. Thyrocare Technologies Limited, Yours Faithfully, Brijesh Kumar Company Secretary and Compliance Officer Encl. A/a Annexure-A Annexure-B Disclosure of information pursuant to Regulation 30 of SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 Re-appointment of Internal Auditor of the Company 1. Name of Internal Auditor M/s. Ernst & Young LLP, Chartered Accountants (“EY”) 2. Reason for change viz. appointment, re- Re-appointment appointment, resignation, removal, death or otherwise 3. Date of appointment/re-appointment/ Date of Re-appointment: July 23, 2026 cessation (as applicable) & term of Term of Appointment: For the Financial appointment/re-appointment; year 2026-27 4. Brief Profile (in case of appointment) EY India is a globally connected, m"Suhlatpidinisgc itphlein faurtyu re pwriothfe csosniofnidaeln ces"ervices organization driven by the purpose of for its clients, people and communities. Through its four service lines - Assurance, Consulting, Tax, and Strategy and Transactions and its deep sector knowledge, EY India helps its clients capitalize on new opportunities, assess and manage risks, deliver responsible growth, fulfil regulatory requirements, keep investors informed, and meet stakeholder needs. EY India has a workforce of over 48,000 professionals with a presence across 16 cities in India, including Ahmedabad, Bengaluru, Bhubaneswar, Chandigarh, Chennai, Gandhinagar, Hyderabad, Jaipur, Kochi, Kolkata, Mumbai, NCR (New Delhi, Gurugram and Noida), Pune and Vadodara. EY India's Risk Consulting services assist clients in transforming their risk and control functions while building confidence among stakeholders. 5. Disclosure of relationships between Not Applicable directors (in case of appointment of a director)